Insmed (INSM) Cash & Equivalents (2010 - 2026)

Insmed has reported Cash & Equivalents for 17 years, with the latest figure at $544.8 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 57.58% year-over-year to $544.8 million in Q2 2026; TTM through Jun 2026 was $544.8 million, a 57.58% decrease from a year earlier, with the FY2025 full-year figure at $510.4 million, down 8.03% from the prior year.
• Cash & Equivalents was $544.8 million for Q2 2026 at Insmed, down from $582.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.3 billion in Q2 2025, with the low at $334.8 million in Q3 2025.
• Average Cash & Equivalents over 5 years is $638.4 million, with a median of $530.3 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents surged 103.43% in 2024, then plunged 57.58% in 2026.
• Over 5 years, Cash & Equivalents stood at $1.1 billion in 2022, then slumped by 55.09% to $482.4 million in 2023, then grew by 15.06% to $555.0 million in 2024, then declined by 8.03% to $510.4 million in 2025, then advanced by 6.73% to $544.8 million in 2026.
• The last three Cash & Equivalents figures came in at $544.8 million (Q2 2026), $582.2 million (Q1 2026), and $510.4 million (Q4 2025), per Business Quant data.